Home > Press Releases > AI in Epidemiology Market

AI in Epidemiology Market Likely to Surpass USD 3.3 Billion by 2035

Report Code: HC-37354 | Published in: Jul 2026, By MarketGenics | Number of pages: 356

Global AI in Epidemiology Market Forecast 2035:

According to the report, the global AI in epidemiology market is likely to grow from USD 0.4 Billion in 2025 to USD 3.3 Billion in 2035 at a highest CAGR of 24.1% during the time period. The proliferation of sophisticated computational intelligence in public health surveillance systems is driving the global AI in epidemiology market, allowing health authorities to analyze vast amounts of disease data in a more timely and accurate manner. This transformation is enhancing the capacity to identify outbreaks earlier, as clinical intelligence, population health patterns and environmental indicators are integrated into common analytical tools.

Epidemiological systems are increasingly focused on multi-layered data-processing architectures that connect increasingly disjointed health information and transform it into structured, real-time intelligence outputs. These systems will help decrease the need for delayed reporting of cases and enhance the responsiveness of health agencies to outbreaks that will be detected more rapidly by geographic area.

Healthcare ecosystems are also transitioning to interwoven public health intelligence networks, facilitating continuous epidemiological monitoring, and coordinated decision and action-making within national and international health institutions, which consequently enhance preparedness, response efficiency and long-term disease control strategies.

“Key Driver, Restraint, and Growth Opportunity Shaping the Global AI in Epidemiology Market”

The rapid advancement of AI in epidemiology has fueled the global AI in Epidemiology market, with healthcare institutions increasingly turning to machine learning models to sift through clinical, genomic, and population-scale data, thereby facilitating early outbreak detection and prompt public health response.

Fragile health data ecosystems and lack of interoperability among hospitals, labs, and public health systems, making it difficult to integrate and standardize health data necessary for robust epidemiological modeling powered by AI.

The new generation of self-learning device architectures is fueling exciting growth, with some personal care products even now being developed that can automatically detect performance degradation, adjust usage parameters and recommend maintenance actions to ensure longer product life cycles, improved efficiency and enhanced personalization and customization with less frequent manual maintenance.

Expansion of Global AI in Epidemiology Market

“Federated Health Intelligence Systems, Real-Time Genomic Surveillance Networks, and Cross-Border Epidemic Data Integration Platforms”

The global AI in epidemiology market is growing as federated health intelligence systems are deployed, allowing hospitals, research centers, and public health agencies to combine data for better disease pattern analysis while maintaining privacy standards to reduce the risk of centralizing patient sensitive information and enhance outbreak detection and epidemiological insights.
Continuous monitoring of pathogen mutations, antimicrobial resistance patterns, and novel variants is enhanced by the increasing use of real-time genomic surveillance and pathogen sequencing networks, which enable ongoing tracking of changes in pathogens and viruses and inform national or regional outbreak modeling and planning for early action.
Moreover, the market is growing with the establishment of new cross-border epidemic data integration platforms that are now creating interoperable AI-based systems to integrate laboratory reports, travel information, and public health data in a unified way, making it easier to coordinate across borders and speed up the response time during infectious disease outbreaks.

Regional Analysis of Global AI in Epidemiology Market

North America holds the largest market share in the global AI in epidemiology market owing to the large-scale use of AI-driven disease surveillance platforms, advanced healthcare IT infrastructure, and abundant real-world health data. There are also significant investments in public health modernization activities, cross-institutional data integration, and advanced analytics to facilitate timely epidemiological intelligence and evidence-based decisions in the region.
Asia Pacific is the fastest-growing region in the global AI in epidemiology market due to the growing healthcare digital infrastructure, funding from government bodies towards improving infectious disease surveillance, and quick uptake of AI technologies in the healthcare sector. The increasing number of population health data available, increasing collaborations for the study of disease, and the faster uptake of cloud-based epidemiology platforms are driving growth in the region.

Prominent players operating in the global AI in epidemiology market Clarivate, Databricks, Inc., International Business Machines Corporation (IBM), IQVIA Inc., SAS Institute Inc., theBlue.ai GmbH, Veradigm LLC, and Other Key Players.

The global AI in epidemiology market has been segmented as follows:

Global AI in Epidemiology Market Analysis, by Component

Software
- Disease Surveillance Software
- Outbreak Prediction & Epidemiological Modeling Software
- Population Health Analytics Software
- Public Health Decision Support Software
- Data Integration & Visualization Software
- AI Reporting & Analytics Software
- Others
Hardware
- AI Servers & High-Performance Computing (HPC) Systems
- Data Storage Systems
- Networking & Communication Infrastructure
- Edge Computing & IoT Devices
- Workstations & Monitoring Devices
- Others
Services
- AI Consulting & System Integration Services
- AI Model Development & Deployment Services
- Managed AI & Cloud Services
- Data Analytics Services
- Technical Support, Training & Compliance Services
- Others

Global AI in Epidemiology Market Analysis, by Technology

Machine Learning (ML)
Deep Learning
Natural Language Processing (NLP)
Computer Vision
Predictive Analytics
Generative AI
Big Data Analytics
Geographic Information Systems (GIS)-Integrated AI
Others

Global AI in Epidemiology Market Analysis, by Deployment Mode

Cloud-Based
On-Premises
Hybrid

Global AI in Epidemiology Market Analysis, by Disease Type

Infectious Diseases
Chronic Diseases
Cardiovascular Diseases
Cancer
Respiratory Diseases
Neurological Disorders
Vector-Borne Diseases
Rare Diseases
Others

Global AI in Epidemiology Market Analysis, by Data Source

Electronic Health Records (EHRs)
Laboratory Data
Genomic Data
Wearable Device Data
Claims & Insurance Data
Social Media Data
Environmental & Climate Data
Public Health Databases
Others

Global AI in Epidemiology Market Analysis, by Application

Disease Surveillance
Outbreak Prediction & Forecasting
Contact Tracing
Population Health Management
Risk Assessment & Modeling
Public Health Decision Support
Clinical Epidemiology
Genomic Epidemiology
Vaccine Surveillance
Antimicrobial Resistance Monitoring
Environmental Health Monitoring
Health Data Analytics
Others

Global AI in Epidemiology Market Analysis, by End User

Public Health Agencies
Hospitals & Healthcare Providers
Research Institutes
Academic Institutions
Pharmaceutical & Biotechnology Companies
Contract Research Organizations (CROs)
Government Organizations
Non-Governmental Organizations (NGOs)
Others

Global AI in Epidemiology Market Analysis, by Region

North America
Europe
Asia Pacific
Middle East
Africa
South America

About Us

MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.

Contact US

USA Address:

800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.

+1(302)303-2617

info@marketgenics.co

India Address:

3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.

sales@marketgenics.co

Table of Contents

1. Research Methodology and Assumptions
- 1.1. Definitions
- 1.2. Research Design and Approach
- 1.3. Data Collection Methods
- 1.4. Base Estimates and Calculations
- 1.5. Forecasting Models
  - 1.5.1. Key Forecast Factors & Impact Analysis
- 1.6. Secondary Research
  - 1.6.1. Open Sources
  - 1.6.2. Paid Databases
  - 1.6.3. Associations
- 1.7. Primary Research
  - 1.7.1. Primary Sources
  - 1.7.2. Primary Interviews with Stakeholders across Ecosystem
2. Executive Summary
- 2.1. Global AI in Epidemiology Market Outlook
  - 2.1.1. AI in Epidemiology Market Size (Value - US$ Bn), and Forecasts, 2021-2035
  - 2.1.2. Compounded Annual Growth Rate Analysis
  - 2.1.3. Growth Opportunity Analysis
  - 2.1.4. Segmental Share Analysis
  - 2.1.5. Geographical Share Analysis
- 2.2. Market Analysis and Facts
- 2.3. Supply-Demand Analysis
- 2.4. Competitive Benchmarking
- 2.5. Go-to- Market Strategy
  - 2.5.1. Customer/ End-use Industry Assessment
  - 2.5.2. Growth Opportunity Data, 2026-2035
    - 2.5.2.1. Regional Data
    - 2.5.2.2. Country Data
    - 2.5.2.3. Segmental Data
  - 2.5.3. Identification of Potential Market Spaces
  - 2.5.4. GAP Analysis
  - 2.5.5. Potential Attractive Price Points
  - 2.5.6. Prevailing Market Risks & Challenges
  - 2.5.7. Preferred Sales & Marketing Strategies
  - 2.5.8. Key Recommendations and Analysis
  - 2.5.9. A Way Forward
3. Industry Data and Premium Insights
- 3.1. Global Healthcare & Pharmaceutical Industry Overview, 2025
  - 3.1.1. Healthcare & Pharmaceutical Industry Ecosystem Analysis
  - 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
  - 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
- 3.2. Supplier Customer Data
- 3.3. Technology Roadmap and Developments
4. Market Overview
- 4.1. Market Dynamics
  - 4.1.1. Drivers
    - 4.1.1.1. Rising adoption of AI for disease surveillance and outbreak prediction
    - 4.1.1.2. Growing availability of real-world health data and electronic health records (EHRs)
    - 4.1.1.3. Increasing government and public health investments in AI-powered epidemiological research
  - 4.1.2. Restraints
    - 4.1.2.1. Data privacy, security, and regulatory compliance challenges
    - 4.1.2.2. Limited availability of high-quality, standardized epidemiological datasets
- 4.2. Key Trend Analysis
- 4.3. Regulatory Framework
  - 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
  - 4.3.2. Tariffs and Standards
  - 4.3.3. Impact Analysis of Regulations on the Market
- 4.4. Ecosystem Analysis
- 4.5. Porter’s Five Forces Analysis
- 4.6. PESTEL Analysis
- 4.7. Global AI in Epidemiology Market Demand
  - 4.7.1. Historical Market Size – Value (US$ Bn), 2020-2024
  - 4.7.2. Current and Future Market Size – Value (US$ Bn), 2026–2035
    - 4.7.2.1. Y-o-Y Growth Trends
    - 4.7.2.2. Absolute $ Opportunity Assessment
5. Competition Landscape
- 5.1. Competition structure
  - 5.1.1. Fragmented v/s consolidated
- 5.2. Company Share Analysis, 2025
  - 5.2.1. Global Company Market Share
  - 5.2.2. By Region
    - 5.2.2.1. North America
    - 5.2.2.2. Europe
    - 5.2.2.3. Asia Pacific
    - 5.2.2.4. Middle East
    - 5.2.2.5. Africa
    - 5.2.2.6. South America
- 5.3. Product Comparison Matrix
  - 5.3.1. Specifications
  - 5.3.2. Market Positioning
  - 5.3.3. Pricing
6. Global AI in Epidemiology Market Analysis, by Component
- 6.1. Key Segment Analysis
- 6.2. AI in Epidemiology Market Size (Value - US$ Bn), Analysis, and Forecasts, by Component, 2021-2035
  - 6.2.1. Software
    - 6.2.1.1. Disease Surveillance Software
    - 6.2.1.2. Outbreak Prediction & Epidemiological Modeling Software
    - 6.2.1.3. Population Health Analytics Software
    - 6.2.1.4. Public Health Decision Support Software
    - 6.2.1.5. Data Integration & Visualization Software
    - 6.2.1.6. AI Reporting & Analytics Software
    - 6.2.1.7. Others
  - 6.2.2. Hardware
    - 6.2.2.1. AI Servers & High-Performance Computing (HPC) Systems
    - 6.2.2.2. Data Storage Systems
    - 6.2.2.3. Networking & Communication Infrastructure
    - 6.2.2.4. Edge Computing & IoT Devices
    - 6.2.2.5. Workstations & Monitoring Devices
    - 6.2.2.6. Others
  - 6.2.3. Services
    - 6.2.3.1. AI Consulting & System Integration Services
    - 6.2.3.2. AI Model Development & Deployment Services
    - 6.2.3.3. Managed AI & Cloud Services
    - 6.2.3.4. Data Analytics Services
    - 6.2.3.5. Technical Support, Training & Compliance Services
    - 6.2.3.6. Others
7. Global AI in Epidemiology Market Analysis, by Technology
- 7.1. Key Segment Analysis
- 7.2. AI in Epidemiology Market Size (Value - US$ Bn), Analysis, and Forecasts, by Technology, 2021-2035
  - 7.2.1. Machine Learning (ML)
  - 7.2.2. Deep Learning
  - 7.2.3. Natural Language Processing (NLP)
  - 7.2.4. Computer Vision
  - 7.2.5. Predictive Analytics
  - 7.2.6. Generative AI
  - 7.2.7. Big Data Analytics
  - 7.2.8. Geographic Information Systems (GIS)-Integrated AI
  - 7.2.9. Others
8. Global AI in Epidemiology Market Analysis, by Deployment Mode
- 8.1. Key Segment Analysis
- 8.2. AI in Epidemiology Market Size (Value - US$ Bn), Analysis, and Forecasts, by Deployment Mode, 2021-2035
  - 8.2.1. Cloud-Based
  - 8.2.2. On-Premises
  - 8.2.3. Hybrid
9. Global AI in Epidemiology Market Analysis, by Disease Type
- 9.1. Key Segment Analysis
- 9.2. AI in Epidemiology Market Size (Value - US$ Bn), Analysis, and Forecasts, by Disease Type, 2021-2035
  - 9.2.1. Infectious Diseases
  - 9.2.2. Chronic Diseases
  - 9.2.3. Cardiovascular Diseases
  - 9.2.4. Cancer
  - 9.2.5. Respiratory Diseases
  - 9.2.6. Neurological Disorders
  - 9.2.7. Vector-Borne Diseases
  - 9.2.8. Rare Diseases
  - 9.2.9. Others
10. Global AI in Epidemiology Market Analysis, by Data Source
- 10.1. Key Segment Analysis
- 10.2. AI in Epidemiology Market Size (Value - US$ Bn), Analysis, and Forecasts, by Data Source, 2021-2035
  - 10.2.1. Electronic Health Records (EHRs)
  - 10.2.2. Laboratory Data
  - 10.2.3. Genomic Data
  - 10.2.4. Wearable Device Data
  - 10.2.5. Claims & Insurance Data
  - 10.2.6. Social Media Data
  - 10.2.7. Environmental & Climate Data
  - 10.2.8. Public Health Databases
  - 10.2.9. Others
11. Global AI in Epidemiology Market Analysis, by Application
- 11.1. Key Segment Analysis
- 11.2. AI in Epidemiology Market Size (Value - US$ Bn), Analysis, and Forecasts, by Application, 2021-2035
  - 11.2.1. Disease Surveillance
  - 11.2.2. Outbreak Prediction & Forecasting
  - 11.2.3. Contact Tracing
  - 11.2.4. Population Health Management
  - 11.2.5. Risk Assessment & Modeling
  - 11.2.6. Public Health Decision Support
  - 11.2.7. Clinical Epidemiology
  - 11.2.8. Genomic Epidemiology
  - 11.2.9. Vaccine Surveillance
  - 11.2.10. Antimicrobial Resistance Monitoring
  - 11.2.11. Environmental Health Monitoring
  - 11.2.12. Health Data Analytics
  - 11.2.13. Others
12. Global AI in Epidemiology Market Analysis, by End User
- 12.1. Key Segment Analysis
- 12.2. AI in Epidemiology Market Size (Value - US$ Bn), Analysis, and Forecasts, by End User, 2021-2035
  - 12.2.1. Public Health Agencies
  - 12.2.2. Hospitals & Healthcare Providers
  - 12.2.3. Research Institutes
  - 12.2.4. Academic Institutions
  - 12.2.5. Pharmaceutical & Biotechnology Companies
  - 12.2.6. Contract Research Organizations (CROs)
  - 12.2.7. Government Organizations
  - 12.2.8. Non-Governmental Organizations (NGOs)
  - 12.2.9. Others
13. Global AI in Epidemiology Market Analysis and Forecasts, by Region
- 13.1. Key Findings
- 13.2. AI in Epidemiology Market Size (Value - US$ Bn), Analysis, and Forecasts, by Region, 2021-2035
  - 13.2.1. North America
  - 13.2.2. Europe
  - 13.2.3. Asia Pacific
  - 13.2.4. Middle East
  - 13.2.5. Africa
  - 13.2.6. South America
14. North America AI in Epidemiology Market Analysis
- 14.1. Key Segment Analysis
- 14.2. Regional Snapshot
- 14.3. North America AI in Epidemiology Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
  - 14.3.1. Component
  - 14.3.2. Technology
  - 14.3.3. Deployment Mode
  - 14.3.4. Disease Type
  - 14.3.5. Data Source
  - 14.3.6. Application
  - 14.3.7. End User
  - 14.3.8. Country
    - 14.3.8.1. USA
    - 14.3.8.2. Canada
    - 14.3.8.3. Mexico
- 14.4. USA AI in Epidemiology Market
  - 14.4.1. Country Segmental Analysis
  - 14.4.2. Component
  - 14.4.3. Technology
  - 14.4.4. Deployment Mode
  - 14.4.5. Disease Type
  - 14.4.6. Data Source
  - 14.4.7. Application
  - 14.4.8. End User
- 14.5. Canada AI in Epidemiology Market
  - 14.5.1. Country Segmental Analysis
  - 14.5.2. Component
  - 14.5.3. Technology
  - 14.5.4. Deployment Mode
  - 14.5.5. Disease Type
  - 14.5.6. Data Source
  - 14.5.7. Application
  - 14.5.8. End User
- 14.6. Mexico AI in Epidemiology Market
  - 14.6.1. Country Segmental Analysis
  - 14.6.2. Component
  - 14.6.3. Technology
  - 14.6.4. Deployment Mode
  - 14.6.5. Disease Type
  - 14.6.6. Data Source
  - 14.6.7. Application
  - 14.6.8. End User
15. Europe AI in Epidemiology Market Analysis
- 15.1. Key Segment Analysis
- 15.2. Regional Snapshot
- 15.3. Europe AI in Epidemiology Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
  - 15.3.1. Component
  - 15.3.2. Technology
  - 15.3.3. Deployment Mode
  - 15.3.4. Disease Type
  - 15.3.5. Data Source
  - 15.3.6. Application
  - 15.3.7. End User
  - 15.3.8. Country
    - 15.3.8.1. Germany
    - 15.3.8.2. United Kingdom
    - 15.3.8.3. France
    - 15.3.8.4. Italy
    - 15.3.8.5. Spain
    - 15.3.8.6. Netherlands
    - 15.3.8.7. Nordic Countries
    - 15.3.8.8. Poland
    - 15.3.8.9. Russia & CIS
    - 15.3.8.10. Rest of Europe
- 15.4. Germany AI in Epidemiology Market
  - 15.4.1. Country Segmental Analysis
  - 15.4.2. Component
  - 15.4.3. Technology
  - 15.4.4. Deployment Mode
  - 15.4.5. Disease Type
  - 15.4.6. Data Source
  - 15.4.7. Application
  - 15.4.8. End User
- 15.5. United Kingdom AI in Epidemiology Market
  - 15.5.1. Country Segmental Analysis
  - 15.5.2. Component
  - 15.5.3. Technology
  - 15.5.4. Deployment Mode
  - 15.5.5. Disease Type
  - 15.5.6. Data Source
  - 15.5.7. Application
  - 15.5.8. End User
- 15.6. France AI in Epidemiology Market
  - 15.6.1. Country Segmental Analysis
  - 15.6.2. Component
  - 15.6.3. Technology
  - 15.6.4. Deployment Mode
  - 15.6.5. Disease Type
  - 15.6.6. Data Source
  - 15.6.7. Application
  - 15.6.8. End User
- 15.7. Italy AI in Epidemiology Market
  - 15.7.1. Country Segmental Analysis
  - 15.7.2. Component
  - 15.7.3. Technology
  - 15.7.4. Deployment Mode
  - 15.7.5. Disease Type
  - 15.7.6. Data Source
  - 15.7.7. Application
  - 15.7.8. End User
- 15.8. Spain AI in Epidemiology Market
  - 15.8.1. Country Segmental Analysis
  - 15.8.2. Component
  - 15.8.3. Technology
  - 15.8.4. Deployment Mode
  - 15.8.5. Disease Type
  - 15.8.6. Data Source
  - 15.8.7. Application
  - 15.8.8. End User
- 15.9. Netherlands AI in Epidemiology Market
  - 15.9.1. Country Segmental Analysis
  - 15.9.2. Component
  - 15.9.3. Technology
  - 15.9.4. Deployment Mode
  - 15.9.5. Disease Type
  - 15.9.6. Data Source
  - 15.9.7. Application
  - 15.9.8. End User
- 15.10. Nordic Countries AI in Epidemiology Market
  - 15.10.1. Country Segmental Analysis
  - 15.10.2. Component
  - 15.10.3. Technology
  - 15.10.4. Deployment Mode
  - 15.10.5. Disease Type
  - 15.10.6. Data Source
  - 15.10.7. Application
  - 15.10.8. End User
- 15.11. Poland AI in Epidemiology Market
  - 15.11.1. Country Segmental Analysis
  - 15.11.2. Component
  - 15.11.3. Technology
  - 15.11.4. Deployment Mode
  - 15.11.5. Disease Type
  - 15.11.6. Data Source
  - 15.11.7. Application
  - 15.11.8. End User
- 15.12. Russia & CIS AI in Epidemiology Market
  - 15.12.1. Country Segmental Analysis
  - 15.12.2. Component
  - 15.12.3. Technology
  - 15.12.4. Deployment Mode
  - 15.12.5. Disease Type
  - 15.12.6. Data Source
  - 15.12.7. Application
  - 15.12.8. End User
- 15.13. Rest of Europe AI in Epidemiology Market
  - 15.13.1. Country Segmental Analysis
  - 15.13.2. Component
  - 15.13.3. Technology
  - 15.13.4. Deployment Mode
  - 15.13.5. Disease Type
  - 15.13.6. Data Source
  - 15.13.7. Application
  - 15.13.8. End User
16. Asia Pacific AI in Epidemiology Market Analysis
- 16.1. Key Segment Analysis
- 16.2. Regional Snapshot
- 16.3. Asia Pacific AI in Epidemiology Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
  - 16.3.1. Component
  - 16.3.2. Technology
  - 16.3.3. Deployment Mode
  - 16.3.4. Disease Type
  - 16.3.5. Data Source
  - 16.3.6. Application
  - 16.3.7. End User
  - 16.3.8. Country
    - 16.3.8.1. China
    - 16.3.8.2. India
    - 16.3.8.3. Japan
    - 16.3.8.4. South Korea
    - 16.3.8.5. Australia and New Zealand
    - 16.3.8.6. Indonesia
    - 16.3.8.7. Malaysia
    - 16.3.8.8. Thailand
    - 16.3.8.9. Vietnam
    - 16.3.8.10. Rest of Asia Pacific
- 16.4. China AI in Epidemiology Market
  - 16.4.1. Country Segmental Analysis
  - 16.4.2. Component
  - 16.4.3. Technology
  - 16.4.4. Deployment Mode
  - 16.4.5. Disease Type
  - 16.4.6. Data Source
  - 16.4.7. Application
  - 16.4.8. End User
- 16.5. India AI in Epidemiology Market
  - 16.5.1. Country Segmental Analysis
  - 16.5.2. Component
  - 16.5.3. Technology
  - 16.5.4. Deployment Mode
  - 16.5.5. Disease Type
  - 16.5.6. Data Source
  - 16.5.7. Application
  - 16.5.8. End User
- 16.6. Japan AI in Epidemiology Market
  - 16.6.1. Country Segmental Analysis
  - 16.6.2. Component
  - 16.6.3. Technology
  - 16.6.4. Deployment Mode
  - 16.6.5. Disease Type
  - 16.6.6. Data Source
  - 16.6.7. Application
  - 16.6.8. End User
- 16.7. South Korea AI in Epidemiology Market
  - 16.7.1. Country Segmental Analysis
  - 16.7.2. Component
  - 16.7.3. Technology
  - 16.7.4. Deployment Mode
  - 16.7.5. Disease Type
  - 16.7.6. Data Source
  - 16.7.7. Application
  - 16.7.8. End User
- 16.8. Australia and New Zealand AI in Epidemiology Market
  - 16.8.1. Country Segmental Analysis
  - 16.8.2. Component
  - 16.8.3. Technology
  - 16.8.4. Deployment Mode
  - 16.8.5. Disease Type
  - 16.8.6. Data Source
  - 16.8.7. Application
  - 16.8.8. End User
- 16.9. Indonesia AI in Epidemiology Market
  - 16.9.1. Country Segmental Analysis
  - 16.9.2. Component
  - 16.9.3. Technology
  - 16.9.4. Deployment Mode
  - 16.9.5. Disease Type
  - 16.9.6. Data Source
  - 16.9.7. Application
  - 16.9.8. End User
- 16.10. Malaysia AI in Epidemiology Market
  - 16.10.1. Country Segmental Analysis
  - 16.10.2. Component
  - 16.10.3. Technology
  - 16.10.4. Deployment Mode
  - 16.10.5. Disease Type
  - 16.10.6. Data Source
  - 16.10.7. Application
  - 16.10.8. End User
- 16.11. Thailand AI in Epidemiology Market
  - 16.11.1. Country Segmental Analysis
  - 16.11.2. Component
  - 16.11.3. Technology
  - 16.11.4. Deployment Mode
  - 16.11.5. Disease Type
  - 16.11.6. Data Source
  - 16.11.7. Application
  - 16.11.8. End User
- 16.12. Vietnam AI in Epidemiology Market
  - 16.12.1. Country Segmental Analysis
  - 16.12.2. Component
  - 16.12.3. Technology
  - 16.12.4. Deployment Mode
  - 16.12.5. Disease Type
  - 16.12.6. Data Source
  - 16.12.7. Application
  - 16.12.8. End User
- 16.13. Rest of Asia Pacific AI in Epidemiology Market
  - 16.13.1. Country Segmental Analysis
  - 16.13.2. Component
  - 16.13.3. Technology
  - 16.13.4. Deployment Mode
  - 16.13.5. Disease Type
  - 16.13.6. Data Source
  - 16.13.7. Application
  - 16.13.8. End User
17. Middle East AI in Epidemiology Market Analysis
- 17.1. Key Segment Analysis
- 17.2. Regional Snapshot
- 17.3. Middle East AI in Epidemiology Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
  - 17.3.1. Component
  - 17.3.2. Technology
  - 17.3.3. Deployment Mode
  - 17.3.4. Disease Type
  - 17.3.5. Data Source
  - 17.3.6. Application
  - 17.3.7. End User
  - 17.3.8. Country
    - 17.3.8.1. Turkey
    - 17.3.8.2. UAE
    - 17.3.8.3. Saudi Arabia
    - 17.3.8.4. Israel
    - 17.3.8.5. Rest of Middle East
- 17.4. Turkey AI in Epidemiology Market
  - 17.4.1. Country Segmental Analysis
  - 17.4.2. Component
  - 17.4.3. Technology
  - 17.4.4. Deployment Mode
  - 17.4.5. Disease Type
  - 17.4.6. Data Source
  - 17.4.7. Application
  - 17.4.8. End User
- 17.5. UAE AI in Epidemiology Market
  - 17.5.1. Country Segmental Analysis
  - 17.5.2. Component
  - 17.5.3. Technology
  - 17.5.4. Deployment Mode
  - 17.5.5. Disease Type
  - 17.5.6. Data Source
  - 17.5.7. Application
  - 17.5.8. End User
- 17.6. Saudi Arabia AI in Epidemiology Market
  - 17.6.1. Country Segmental Analysis
  - 17.6.2. Component
  - 17.6.3. Technology
  - 17.6.4. Deployment Mode
  - 17.6.5. Disease Type
  - 17.6.6. Data Source
  - 17.6.7. Application
  - 17.6.8. End User
- 17.7. Israel AI in Epidemiology Market
  - 17.7.1. Country Segmental Analysis
  - 17.7.2. Component
  - 17.7.3. Technology
  - 17.7.4. Deployment Mode
  - 17.7.5. Disease Type
  - 17.7.6. Data Source
  - 17.7.7. Application
  - 17.7.8. End User
- 17.8. Rest of Middle East AI in Epidemiology Market
  - 17.8.1. Country Segmental Analysis
  - 17.8.2. Component
  - 17.8.3. Technology
  - 17.8.4. Deployment Mode
  - 17.8.5. Disease Type
  - 17.8.6. Data Source
  - 17.8.7. Application
  - 17.8.8. End User
18. Africa AI in Epidemiology Market Analysis
- 18.1. Key Segment Analysis
- 18.2. Regional Snapshot
- 18.3. Africa AI in Epidemiology Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
  - 18.3.1. Component
  - 18.3.2. Technology
  - 18.3.3. Deployment Mode
  - 18.3.4. Disease Type
  - 18.3.5. Data Source
  - 18.3.6. Application
  - 18.3.7. End User
  - 18.3.8. Country
    - 18.3.8.1. South Africa
    - 18.3.8.2. Egypt
    - 18.3.8.3. Nigeria
    - 18.3.8.4. Algeria
    - 18.3.8.5. Rest of Africa
- 18.4. South Africa AI in Epidemiology Market
  - 18.4.1. Country Segmental Analysis
  - 18.4.2. Component
  - 18.4.3. Technology
  - 18.4.4. Deployment Mode
  - 18.4.5. Disease Type
  - 18.4.6. Data Source
  - 18.4.7. Application
  - 18.4.8. End User
- 18.5. Egypt AI in Epidemiology Market
  - 18.5.1. Country Segmental Analysis
  - 18.5.2. Component
  - 18.5.3. Technology
  - 18.5.4. Deployment Mode
  - 18.5.5. Disease Type
  - 18.5.6. Data Source
  - 18.5.7. Application
  - 18.5.8. End User
- 18.6. Nigeria AI in Epidemiology Market
  - 18.6.1. Country Segmental Analysis
  - 18.6.2. Component
  - 18.6.3. Technology
  - 18.6.4. Deployment Mode
  - 18.6.5. Disease Type
  - 18.6.6. Data Source
  - 18.6.7. Application
  - 18.6.8. End User
- 18.7. Algeria AI in Epidemiology Market
  - 18.7.1. Country Segmental Analysis
  - 18.7.2. Component
  - 18.7.3. Technology
  - 18.7.4. Deployment Mode
  - 18.7.5. Disease Type
  - 18.7.6. Data Source
  - 18.7.7. Application
  - 18.7.8. End User
- 18.8. Rest of Africa AI in Epidemiology Market
  - 18.8.1. Country Segmental Analysis
  - 18.8.2. Component
  - 18.8.3. Technology
  - 18.8.4. Deployment Mode
  - 18.8.5. Disease Type
  - 18.8.6. Data Source
  - 18.8.7. Application
  - 18.8.8. End User
19. South America AI in Epidemiology Market Analysis
- 19.1. Key Segment Analysis
- 19.2. Regional Snapshot
- 19.3. South America AI in Epidemiology Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
  - 19.3.1. Component
  - 19.3.2. Technology
  - 19.3.3. Deployment Mode
  - 19.3.4. Disease Type
  - 19.3.5. Data Source
  - 19.3.6. Application
  - 19.3.7. End User
  - 19.3.8. Country
    - 19.3.8.1. Brazil
    - 19.3.8.2. Argentina
    - 19.3.8.3. Rest of South America
- 19.4. Brazil AI in Epidemiology Market
  - 19.4.1. Country Segmental Analysis
  - 19.4.2. Component
  - 19.4.3. Technology
  - 19.4.4. Deployment Mode
  - 19.4.5. Disease Type
  - 19.4.6. Data Source
  - 19.4.7. Application
  - 19.4.8. End User
- 19.5. Argentina AI in Epidemiology Market
  - 19.5.1. Country Segmental Analysis
  - 19.5.2. Component
  - 19.5.3. Technology
  - 19.5.4. Deployment Mode
  - 19.5.5. Disease Type
  - 19.5.6. Data Source
  - 19.5.7. Application
  - 19.5.8. End User
- 19.6. Rest of South America AI in Epidemiology Market
  - 19.6.1. Country Segmental Analysis
  - 19.6.2. Component
  - 19.6.3. Technology
  - 19.6.4. Deployment Mode
  - 19.6.5. Disease Type
  - 19.6.6. Data Source
  - 19.6.7. Application
  - 19.6.8. End User
20. Key Players/ Company Profile
- 20.1. Clarivate.
  - 20.1.1. Company Details/ Overview
  - 20.1.2. Company Financials
  - 20.1.3. Key Customers and Competitors
  - 20.1.4. Business/ Industry Portfolio
  - 20.1.5. Product Portfolio/ Specification Details
  - 20.1.6. Pricing Data
  - 20.1.7. Strategic Overview
  - 20.1.8. Recent Developments
- 20.2. Databricks, Inc.
- 20.3. International Business Machines Corporation (IBM)
- 20.4. IQVIA Inc.
- 20.5. SAS Institute Inc.
- 20.6. theBlue.ai GmbH
- 20.7. Veradigm LLC
- 20.8. Other Key Players

Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography

Get PDF

PRICING DETAILS

Single-User Upto 2 Users - [PDF + Excel Only]

USD 4150

Multi-User Upto 10 Users - [PDF + Excel + PPT]

USD 5950

Enterprise-User Company-wide - [Report Pack + Benchmark + 6M Update]

USD 7750

Related Report

Discount On Multiple Reports

Where did We Help Most?

Custom Market Research Services

We will customise the research for you, in case the report listed above does not meet your requirements.

Get 10% Free Customisation